ClinicalTrials.gg
CompletedNCT04973228Updated Mar 12, 2024Results posted

Trial of PDE4 Inhibition With Roflumilast (ARQ-154) Foam 0.3% for the Management of Seborrheic Dermatitis (STRATUM)

A Phase 3 interventional study of Roflumilast Foam and Vehicle Foam in Seborrheic Dermatitis, sponsored by Arcutis Biotherapeutics, Inc.. Completed at 53 sites in 2 countries. Open to participants aged 9 Years and older. Per ClinicalTrials.gov, last updated 2024-03-12.

Sponsored by Arcutis Biotherapeutics, Inc. · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
457
Allocation
Randomized
Ages
9 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 19 studies in Dermatitis, Seborrheic with a site in United States — 1 open to participants now, 1 under way, none of them phase 3. Dermatitis, Seborrheic · United States.

Enrollment
Largest of 18
457 · median 62
Started
2021
the only one that year
Phase 3
Only one
of the 19
Registered
15th of 19
by date
Lead sponsor
3 of 19
Arcutis Biotherapeutics, Inc.

Among the 19 studies in Dermatitis, Seborrheic with a site in United States, this one has the largest enrollment of the 18 interventional ones that give a count, is the only one that started in 2021, is the only one in phase 3, and was the 15th registered.

Dermatitis, Seborrheic

58 studies on the registry are indexed under Dermatitis, Seborrheic; 7 are open to participants now.

Browse Dermatitis, Seborrheic studies →

Open to participants now

1 of the 19 studies in Dermatitis, Seborrheic with a site in United States is open now. Recruiting first, the newest first:

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 4 Dermatitis, Seborrheic studies recruiting now, 1 sets no upper age limit and 3 stop at 75 or younger; none take children under 18; 2 take healthy volunteers.

This study: 9 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 19 studies in Dermatitis, Seborrheic with a site in United States, or all of them as a file.
02

Study summary

This phase 3, double-blind, vehicle-controlled study assessed the safety and efficacy of roflumilast (ARQ-154) foam 0.3% applied once daily (qd) for 8 weeks by participants with seborrheic dermatitis.

03

Conditions studied

  • Seborrheic Dermatitis

Browse trials for

04

Who can participate

Ages eligible
9 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Participants legally competent to sign and give and, if appropriate, assent as required by local laws.
  • Males and females ages 9 years and older at the time of consent.
  • Clinical diagnosis of seborrheic dermatitis of at least 3 months duration at Screening as determined by the Investigator. Stable disease for the past 4 weeks.
  • Seborrheic dermatitis up to 20% BSA involvement. Involvement may be of the scalp and/or face and/or trunk and/or intertriginous areas.
  • An Investigator Global Assessment (IGA) disease severity of at least Moderate ('3') at Baseline.
  • Overall Assessment of Erythema and Overall Assessment of Scaling scores of at least Moderate ('2') at Baseline.
  • Females of (FOCBP) must have a negative serum pregnancy test at Screening (Visit 1) and a negative urine pregnancy test at Baseline (Visit 2).
  • Females of non-childbearing potential must either be with spontaneous amenorrhea for at least 12 months or have undergone surgical sterilization.
  • Subjects in good health as judged by the Investigator.
  • Subjects are considered reliable and capable of adhering to the Protocol and visit schedule according to the Investigator judgment.

Key Exclusion Criteria:

  • Subjects who cannot discontinue treatment with therapies for the treatment of seborrheic dermatitis prior to the Baseline visit and during the study.
  • Planned excessive exposure of treated area(s) to either natural or artificial sunlight, tanning bed or other LED.
  • Previous treatment with ARQ-154 or ARQ-151.
  • Subjects with any serious medical condition or abnormality that would prevent study participation or place the subject at significant risk, as judged by the Investigator.
  • Females who are pregnant, wishing to become pregnant during the study, or are breast-feeding.
  • Subjects with a history of chronic alcohol or drug abuse within 6 months prior to Screening.
  • Subjects, parent(s)/legal guardian(s) who are unable to communicate, read, or understand the local language(s).
  • Subjects who are family members of the clinical study site, clinical study staff, or sponsor, or family members living in the same house of enrolled subjects.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
457 participants (actual)

Study arms

  • Experimental
    Roflumilast Foam 0.3%

    Participants with seborrheic dermatitis apply roflumilast foam 0.3% once daily (QD) for 8 weeks.

    Drug: Roflumilast Foam

  • Placebo comparator
    Vehicle Foam

    Participants with seborrheic dermatitis apply vehicle foam QD for 8 weeks.

    Drug: Vehicle Foam

Interventions

  • Roflumilast 0.3% foam for topical application

    Also known as: ARQ-154

  • DrugVehicle Foam

    Vehicle foam for topical application

06

What researchers measure

Primary outcomes

  1. Achievement of Success on the Investigator Global Assessment (IGA) at Week 8

    The percentage of participants achieving IGA "success" is presented. Success is defined as a score of 0 ('clear') or 1 ('almost clear') plus a 2-point improvement at Week 8. The IGA is 5-point scale assessing the severity of seborrheic dermatitis with total scores ranging from 0 ('clear') to 4 ('severe') \[higher scores indicating greater severity\].

    Time frame: Week 8

Secondary outcomes

  1. Achievement of Success in the Worst Itch Numeric Rating Scale (WI-NRS) at Week 8

    The percentage of participants achieving WI-NRS "success" is presented. The WI-NRS is a simple, single-item scale to assess the participant-reported severity of this symptom, on a scale ranging from 0 ("no itch") to 10 ("worst imaginable itch") the participants experienced in the previous 24 hours (higher scores indicate higher itch severity). The endpoint is the average of daily assessments reported during each study week, and requires at least 4 daily assessments reported during the week. In participants with a weekly average baseline pruritus score of ≥4, "success" is defined as achievement of a ≥4-point improvement from baseline in weekly average WI-NRS pruritus score at Week 8.

    Time frame: Week 8

  2. Achievement of Success in the WI-NRS at Week 4

    The percentage of participants achieving WI-NRS "success" is presented. The WI-NRS is a simple, single-item scale to assess the participant-reported severity of this symptom, on a scale ranging from 0 ("no itch") to 10 ("worst imaginable itch") the participants experienced in the previous 24 hours (higher scores indicate higher itch severity). The endpoint is the average of daily assessments reported during each study week, and requires at least 4 daily assessments reported during the week. In participants with a weekly average baseline pruritus score of ≥4, "success" is defined as achievement of a ≥4-point improvement from baseline in weekly average WI-NRS pruritus score at Week 4.

    Time frame: Week 4

  3. Achievement of Success in the WI-NRS at Week 2

    The percentage of participants achieving WI-NRS "success" is presented. In participants with a weekly average baseline pruritus score of ≥4, "success" is defined as achievement of a ≥4-point improvement from baseline in weekly average WI-NRS pruritus score at Week 2. The endpoint is the average of daily assessments reported during each study week, and requires at least 4 daily assessments reported during the week. The WI-NRS is a simple, single-item scale to assess the participant-reported severity of this symptom, on a scale ranging from 0 ("no itch") to 10 ("worst imaginable itch") the participants experienced in the previous 24 hours (higher scores indicate higher itch severity).

    Time frame: Week 2

  4. Achievement of Success on the IGA at Week 2

    The percentage of participants achieving WI-NRS "success" is presented. The WI-NRS is a simple, single-item scale to assess the participant-reported severity of this symptom, on a scale ranging from 0 ("no itch") to 10 ("worst imaginable itch") the participants experienced in the previous 24 hours (higher scores indicate higher itch severity). The endpoint is the average of daily assessments reported during each study week, and requires at least 4 daily assessments reported during the week. In participants with a weekly average baseline pruritus score of ≥4, "success" is defined as achievement of a ≥4-point improvement from baseline in weekly average WI-NRS pruritus score at Week 2.

    Time frame: Week 2

  5. Achievement of Success on the IGA at Week 4

    The percentage of participants achieving IGA "success" is presented. Success is defined as a score of 0 ('clear') or 1 ('almost clear') plus a 2-point improvement at Week 8. The IGA is 5-point scale assessing the severity of seborrheic dermatitis with total scores ranging from 0 ('clear') to 4 ('severe') \[higher scores indicating greater severity\].

    Time frame: Week 4

  6. Achievement of Overall Assessment of Scaling Score of 0 at Week 8

    The percentage of participants achieving Overall Assessment of Scaling score of 0 at Week 8 is presented. The Overall Assessment of Scaling is a simple, single-item scale to assess the subject-reported severity of this symptom, on a scale ranging from 0 ("No scaling: No scaling evident on lesions.") to 3 ("Severe: Coarse, thick scales, with flaking into clothes or skin."). Higher scores indicate greater symptom severity.

    Time frame: Week 8

  7. Achievement of Overall Assessment of Erythema Score of 0 at Week 8

    The percentage of participants achieving Overall Assessment of Erythema score of 0 at Week 8 is presented. The Erythema Assessment is a simple, single-item scale to assess the subject-reported severity of this symptom, on a scale ranging from 0 ("None: no evidence of erythema.") to 3 ("Severe: Intense \[fiery red\] erythema."). Higher scores indicate greater severity.

    Time frame: Week 8

07

Results

Posted Mar 12, 2024

Participant flow

Participant flow — Overall Study
MilestoneRoflumilast Foam 0.3%Vehicle Foam
Started304153
Completed276138
Not completed2815
Withdrew: Adverse event23
Withdrew: Lack of efficacy13
Withdrew: Lost to follow-up124
Withdrew: Withdrawal by subject114
Withdrew: Did not tolerate application10
Withdrew: Wanted to early terminate and use own product01
Withdrew: Missed visits due to new work schedule10

Outcome measures

PrimaryAchievement of Success on the Investigator Global Assessment (IGA) at Week 8

The percentage of participants achieving IGA "success" is presented. Success is defined as a score of 0 ('clear') or 1 ('almost clear') plus a 2-point improvement at Week 8. The IGA is 5-point scale assessing the severity of seborrheic dermatitis with total scores ranging from 0 ('clear') to 4 ('severe') \[higher scores indicating greater severity\].

Time frame:
Week 8
Reported as:
Number · percentage of participants
Achievement of Success on the Investigator Global Assessment (IGA) at Week 8
percentage of participantsRoflumilast Foam 0.3%Vehicle Foam
Achievement of Success on the Investigator Global Assessment (IGA) at Week 880 (74 to 84)58 (50 to 66)
Statistical analysis
  • Roflumilast Foam 0.3% vs Vehicle Foam · Cochran-Mantel-Haenszel · p = <0.0001 · Odds ratio (or): 2.79 · 95% CI 1.75 to 4.45Stratified by pooled site and IGA strata with multiple imputation to handle missing data
SecondaryAchievement of Success in the Worst Itch Numeric Rating Scale (WI-NRS) at Week 8

The percentage of participants achieving WI-NRS "success" is presented. The WI-NRS is a simple, single-item scale to assess the participant-reported severity of this symptom, on a scale ranging from 0 ("no itch") to 10 ("worst imaginable itch") the participants experienced in the previous 24 hours (higher scores indicate higher itch severity). The endpoint is the average of daily assessments reported during each study week, and requires at least 4 daily assessments reported during the week. In participants with a weekly average baseline pruritus score of ≥4, "success" is defined as achievement of a ≥4-point improvement from baseline in weekly average WI-NRS pruritus score at Week 8.

Time frame:
Week 8
Reported as:
Number · percentage of participants
Achievement of Success in the Worst Itch Numeric Rating Scale (WI-NRS) at Week 8
percentage of participantsRoflumilast Foam 0.3%Vehicle Foam
Achievement of Success in the Worst Itch Numeric Rating Scale (WI-NRS) at Week 863 (56 to 70)41 (31 to 51)
Statistical analysis
  • Roflumilast Foam 0.3% vs Vehicle Foam · Cochran-Mantel-Haenszel · p = 0.0001 · Odds ratio (or): 2.95 · 95% CI 1.68 to 5.19Stratified by pooled site and IGA strata with multiple imputation to handle missing data
SecondaryAchievement of Success in the WI-NRS at Week 4

The percentage of participants achieving WI-NRS "success" is presented. The WI-NRS is a simple, single-item scale to assess the participant-reported severity of this symptom, on a scale ranging from 0 ("no itch") to 10 ("worst imaginable itch") the participants experienced in the previous 24 hours (higher scores indicate higher itch severity). The endpoint is the average of daily assessments reported during each study week, and requires at least 4 daily assessments reported during the week. In participants with a weekly average baseline pruritus score of ≥4, "success" is defined as achievement of a ≥4-point improvement from baseline in weekly average WI-NRS pruritus score at Week 4.

Time frame:
Week 4
Reported as:
Number · percentage of participants
Achievement of Success in the WI-NRS at Week 4
percentage of participantsRoflumilast Foam 0.3%Vehicle Foam
Achievement of Success in the WI-NRS at Week 448 (41 to 54)29 (21 to 39)
Statistical analysis
  • Roflumilast Foam 0.3% vs Vehicle Foam · Cochran-Mantel-Haenszel · p = 0.0007 · Odds ratio (or): 2.62 · 95% CI 1.47 to 4.67Stratified by pooled site and IGA strata with multiple imputation to handle missing data
SecondaryAchievement of Success in the WI-NRS at Week 2

The percentage of participants achieving WI-NRS "success" is presented. In participants with a weekly average baseline pruritus score of ≥4, "success" is defined as achievement of a ≥4-point improvement from baseline in weekly average WI-NRS pruritus score at Week 2. The endpoint is the average of daily assessments reported during each study week, and requires at least 4 daily assessments reported during the week. The WI-NRS is a simple, single-item scale to assess the participant-reported severity of this symptom, on a scale ranging from 0 ("no itch") to 10 ("worst imaginable itch") the participants experienced in the previous 24 hours (higher scores indicate higher itch severity).

Time frame:
Week 2
Reported as:
Number · percentage of participants
Achievement of Success in the WI-NRS at Week 2
percentage of participantsRoflumilast Foam 0.3%Vehicle Foam
Achievement of Success in the WI-NRS at Week 233 (27 to 40)16 (10 to 24)
Statistical analysis
  • Roflumilast Foam 0.3% vs Vehicle Foam · Cochran-Mantel-Haenszel · p = 0.0016 · Odds ratio (or): 2.74 · 95% CI 1.41 to 5.34Stratified by pooled site and IGA strata with multiple imputation to handle missing data
SecondaryAchievement of Success on the IGA at Week 2

The percentage of participants achieving WI-NRS "success" is presented. The WI-NRS is a simple, single-item scale to assess the participant-reported severity of this symptom, on a scale ranging from 0 ("no itch") to 10 ("worst imaginable itch") the participants experienced in the previous 24 hours (higher scores indicate higher itch severity). The endpoint is the average of daily assessments reported during each study week, and requires at least 4 daily assessments reported during the week. In participants with a weekly average baseline pruritus score of ≥4, "success" is defined as achievement of a ≥4-point improvement from baseline in weekly average WI-NRS pruritus score at Week 2.

Time frame:
Week 2
Reported as:
Number · percentage of participants
Achievement of Success on the IGA at Week 2
percentage of participantsRoflumilast Foam 0.3%Vehicle Foam
Achievement of Success on the IGA at Week 243 (37 to 49)26 (19 to 33)
Statistical analysis
  • Roflumilast Foam 0.3% vs Vehicle Foam · Cochran-Mantel-Haenszel · p = 0.0002 · Odds ratio (or): 2.43 · 95% CI 1.54 to 3.84Pooled by site and IGA strata with multiple imputation to handle missing data
SecondaryAchievement of Success on the IGA at Week 4

The percentage of participants achieving IGA "success" is presented. Success is defined as a score of 0 ('clear') or 1 ('almost clear') plus a 2-point improvement at Week 8. The IGA is 5-point scale assessing the severity of seborrheic dermatitis with total scores ranging from 0 ('clear') to 4 ('severe') \[higher scores indicating greater severity\].

Time frame:
Week 4
Reported as:
Number · percentage of participants
Achievement of Success on the IGA at Week 4
percentage of participantsRoflumilast Foam 0.3%Vehicle Foam
Achievement of Success on the IGA at Week 473.1 (67.67 to 77.83)47.1 (39.19 to 55.10)
Statistical analysis
  • Roflumilast Foam 0.3% vs Vehicle Foam · Cochran-Mantel-Haenszel · p = <0.0001 · Odds ratio (or): 3.22 · 95% CI 2.06 to 5.03Pooled by site and IGA strata with multiple imputation to handle missing data
SecondaryAchievement of Overall Assessment of Scaling Score of 0 at Week 8

The percentage of participants achieving Overall Assessment of Scaling score of 0 at Week 8 is presented. The Overall Assessment of Scaling is a simple, single-item scale to assess the subject-reported severity of this symptom, on a scale ranging from 0 ("No scaling: No scaling evident on lesions.") to 3 ("Severe: Coarse, thick scales, with flaking into clothes or skin."). Higher scores indicate greater symptom severity.

Time frame:
Week 8
Reported as:
Number · percentage of participants
Achievement of Overall Assessment of Scaling Score of 0 at Week 8
percentage of participantsRoflumilast Foam 0.3%Vehicle Foam
Achievement of Overall Assessment of Scaling Score of 0 at Week 858 (52 to 63)37 (29 to 45)
Statistical analysis
  • Roflumilast Foam 0.3% vs Vehicle Foam · Cochran-Mantel-Haenszel · p = <0.0001 · Odds ratio (or): 2.41 · 95% CI 1.56 to 3.73Stratified by pooled site and IGA strata with multiple imputation to handle missing data
SecondaryAchievement of Overall Assessment of Erythema Score of 0 at Week 8

The percentage of participants achieving Overall Assessment of Erythema score of 0 at Week 8 is presented. The Erythema Assessment is a simple, single-item scale to assess the subject-reported severity of this symptom, on a scale ranging from 0 ("None: no evidence of erythema.") to 3 ("Severe: Intense \[fiery red\] erythema."). Higher scores indicate greater severity.

Time frame:
Week 8
Reported as:
Number · percentage of participants
Achievement of Overall Assessment of Erythema Score of 0 at Week 8
percentage of participantsRoflumilast Foam 0.3%Vehicle Foam
Achievement of Overall Assessment of Erythema Score of 0 at Week 858 (52 to 63)32 (25 to 40)
Statistical analysis
  • Roflumilast Foam 0.3% vs Vehicle Foam · Cochran-Mantel-Haenszel · p = <0.0001 · Odds ratio (or): 3.22 · 95% CI 2.05 to 5.06Stratified by pooled site and IGA strata with multiple imputation to handle missing data

Adverse events

Collected over Up to ~8 weeks. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Roflumilast Foam 0.3%0/304 (0%)1/304 (0.3%)0/304 (0%)
Vehicle Foam0/153 (0%)0/153 (0%)0/153 (0%)
Most frequent serious events
Most frequent serious events
EventRoflumilast Foam 0.3%Vehicle Foam
KeratoacanthomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/3040/153

Baseline characteristics

Age, Continuous
Age, Continuous(years)Roflumilast Foam 0.3%Vehicle FoamTotal
Mean43.2 ± 16.8141.8 ± 17.4742.7 ± 17.03
Sex: Female, Male
Sex: Female, Male(Participants)Roflumilast Foam 0.3%Vehicle FoamTotal
Female15178229
Male15375228
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Roflumilast Foam 0.3%Vehicle FoamTotal
Hispanic or Latino692897
Not Hispanic or Latino235125360
Unknown or Not Reported000
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Roflumilast Foam 0.3%Vehicle FoamTotal
American Indian or Alaska Native404
Asian181028
Native Hawaiian or Other Pacific Islander011
Black or African American361551
White234122356
More than one race112
Other11415
Investigator Global Assessment (IGA) Baseline Score
Investigator Global Assessment (IGA) Baseline Score(Participants)Roflumilast Foam 0.3%Vehicle FoamTotal
2 - Mild000
3 - Moderate287141428
4 - Severe171229
Worst Itch Numerical Rating Scale (WI-NRS) Baseline Score
Worst Itch Numerical Rating Scale (WI-NRS) Baseline Score(Participants)Roflumilast Foam 0.3%Vehicle FoamTotal
020929
1131427
2221032
3351651
4261541
5432063
6402262
7391756
8331649
914721
1012618
08

Study locations

53 sites
  • Arcutis Biotherapeutics Clinical Site 01
    Scottsdale, Arizona 85255, United States
  • Arcutis Biotherapeutics Clinical Site 45
    Encinitas, California 92024, United States
  • Arcutis Biotherapeutics Clinical Site 46
    San Diego, California 92123, United States
  • Arcutis Biotherapeutics Clinical Site 64
    San Diego, California 92123, United States
  • Arcutis Biotherapeutics Clinical Site 21
    Santa Monica, California 90404, United States
  • Arcutis Biotherapeutics Clinical Site 42
    Coral Gables, Florida 33134, United States
  • Arcutis Biotherapeutics Clinical Site 57
    Delray Beach, Florida 33484, United States
  • Arcutis Biotherapeutics Clinical Site 33
    Largo, Florida 33770, United States
  • Arcutis Biotherapeutics Clinical Site 31
    North Miami Beach, Florida 33162, United States
  • Arcutis Biotherapeutics Clinical Site 65
    Sanford, Florida 32771, United States
  • Arcutis Biotherapeutics Clinical Site 12
    Tampa, Florida 33613, United States
  • Arcutis Biotherapeutics Clinical Site 10
    Rolling Meadows, Illinois 60008, United States
  • Arcutis Biotherapeutics Clinical Site 03
    Indianapolis, Indiana 46250, United States
  • Arcutis Biotherapeutics Clinical Site 22
    Plainfield, Indiana 46168, United States
  • Arcutis Biotherapeutics Clinical Site 15
    Louisville, Kentucky 40217, United States
  • Arcutis Biotherapeutics Clinical Site 04
    Lake Charles, Louisiana 70605, United States
  • Arcutis Biotherapeutics Clinical Site 02
    Rockville, Maryland 20850, United States
  • Arcutis Biotherapeutics Clinical Site 28
    Rockville, Maryland 20850, United States
  • Arcutis Biotherapeutics Clinical Site 40
    Clinton Township, Michigan 48038, United States
  • Arcutis Biotherapeutics Clinical Site 20
    Detroit, Michigan 48202, United States
  • Arcutis Biotherapeutics Clinical Site 14
    Fridley, Minnesota 55432, United States
  • Arcutis Biotherapeutics Clinical Site 44
    Saint Joseph, Missouri 64506, United States
  • Arcutis Biotherapeutics Clinical Site 19
    Reno, Nevada 89509, United States
  • Arcutis Biotherapeutics Clinical Site 34
    East Windsor, New Jersey 08520, United States
  • Arcutis Biotherapeutics Clinical Site 63
    Bronx, New York 10462, United States
  • Arcutis Biotherapeutics Clinical Site 66
    New York, New York 10065, United States
  • Arcutis Biotherapeutics Clinical Site 23
    High Point, North Carolina 27262, United States
  • Arcutis Biotherapeutics Clinical Site 70
    Winston-Salem, North Carolina 27104, United States
  • Arcutis Biotherapeutics Clinical Site 18
    Bexley, Ohio 43209, United States
  • Arcutis Biotherapeutics Clinical Site 71
    Portland, Oregon 97223, United States
  • Arcutis Biotherapeutics Clinical Site 08
    Broomall, Pennsylvania 19008, United States
  • Arcutis Biotherapeutics Clinical Site 27
    Pittsburgh, Pennsylvania 15213, United States
  • Arcutis Biotherapeutics Clinical Site 06
    Knoxville, Tennessee 37922, United States
  • Arcutis Biotherapeutics Clinical Site 13
    Arlington, Texas 76011, United States
  • Arcutis Biotherapeutics Clinical Site 11
    Austin, Texas 78759, United States
  • Arcutis Biotherapeutics Clinical Site 41
    College Station, Texas 77845, United States
  • Arcutis Biotherapeutics Clinical Site 60
    Houston, Texas 77030, United States
  • Arcutis Biotherapeutics Clinical Site 26
    Pflugerville, Texas 78660, United States
  • Arcutis Biotherapeutics Clinical Site 72
    Plano, Texas 75024, United States
  • Arcutis Biotherapeutics Clinical Site 54
    San Antonio, Texas 78213, United States
  • Arcutis Biotherapeutics Clinical Site 24
    San Antonio, Texas 78218, United States
  • Arcutis Biotherapeutics Clinical Site 07
    West Jordan, Utah 84088, United States
  • Arcutis Biotherapeutics Clinical Site 17
    Norfolk, Virginia 23502, United States
  • Arcutis Biotherapeutics Clinical Site 35
    Calgary, Alberta T2J 7E1, Canada
  • Arcutis Biotherapeutics Clinical Site 37
    Surrey, British Columbia V3V 0C6, Canada
  • Arcutis Biotherapeutics Clinical Site 47
    Winnipeg, Manitoba R3M 3Z4, Canada
  • Arcutis Biotherapeutics Clinical Site 43
    Fredericton, New Brunswick E3B 1G9, Canada
  • Arcutis Biotherapeutics Clinical Site 16
    London, Ontario N6H 5L5, Canada
  • Arcutis Biotherapeutics Clinical Site 29
    Mississauga, Ontario L5H 1G9, Canada
  • Arcutis Biotherapeutics Clinical Site 30
    North Bay, Ontario P1B 3Z7, Canada
  • Arcutis Biotherapeutics Clinical Site 32
    Peterborough, Ontario K9J 5K2, Canada
  • Arcutis Biotherapeutics Clinical Site 36
    Waterloo, Ontario N2J 1C4, Canada
  • Arcutis Biotherapeutics Clinical Site 09
    Westmount, Quebec H3Z 2S6, Canada
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jul 2021 to primary completion in Apr 2022, 8 months.

Results were first posted in Mar 2024, 1 year 11 months after primary completion. A results delay was requested in Mar 2023.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 13, 2021
First posted
Jul 22, 2021
StartActual
Jul 8, 2021
Primary completionActual
Apr 6, 2022
CompletionActual
Apr 6, 2022
Results delay requested
Mar 7, 2023
Results first posted
Mar 12, 2024
Last update
Mar 12, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 12, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04973228
Responsible party
Sponsor
First posted
Jul 22, 2021
Start date
Jul 8, 2021
Primary completion
Apr 6, 2022
Completion
Apr 6, 2022
Results posted
Mar 12, 2024
Last update
Mar 12, 2024

Study contacts

David Berk, MD
study director · Arcutis Biotherapeutics, Inc.

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: ARQ-154

Start the discussion